20 Article List RSS https://www.biospace.com/articlesrss/ Tue, 09 May 2023 00:04:57 -0500 Tue, 09 May 2023 00:04:57 -0500 BioSpace Boehringer Ingelheim to Mine Ginkgo’s Molecules in $406M Undruggable Targets Deal ]]>Partnership seeks to identify novel therapeutic molecules to address diseases with high unmet patient needs. It’s the second target discovery company to link with BI in the last month. https://www.biospace.com/article/boehringer-ingelheim-to-mine-ginkgo-s-molecules-in-406m-undruggable-targets-deal/ Mon, 08 May 2023 00:00:00 -0500 https://www.biospace.com/article/boehringer-ingelheim-to-mine-ginkgo-s-molecules-in-406m-undruggable-targets-deal/ Takeda Cuts 180+ Jobs Amid Pipeline Shake-Up ]]>Takeda plans to cut about 186 staff members across Massachusetts, beginning in early July.  https://www.biospace.com/article/takeda-cuts-180-jobs-amid-pipeline-shake-up/ Mon, 08 May 2023 15:11:00 -0500 https://www.biospace.com/article/takeda-cuts-180-jobs-amid-pipeline-shake-up/ BioNTech Looks to Expand into Other Markets as COVID-19 Revenues Dwindle ]]>The German biotech is trying to deepen its pipeline in cancer and other infectious diseases as COVID-19 markets contract and the international public health emergency comes to an end. https://www.biospace.com/article/biontech-looks-to-expand-into-other-markets-as-covid-19-revenues-dwindle/ Mon, 08 May 2023 00:00:00 -0500 https://www.biospace.com/article/biontech-looks-to-expand-into-other-markets-as-covid-19-revenues-dwindle/ BMS Cuts Jobs in New Jersey, Cites ‘Constantly Evolving’ Business Model  ]]>Weeks after announcing a CEO shake-up and slightly decreased Q1 revenues, BMS plans to cut 48 staff members from its Princeton, NJ, facility.  https://www.biospace.com/article/bms-cuts-jobs-in-new-jersey-cites-constantly-evolving-business-model-/ Mon, 08 May 2023 00:00:00 -0500 https://www.biospace.com/article/bms-cuts-jobs-in-new-jersey-cites-constantly-evolving-business-model-/ Biopharma Bets Big on Antibody-Drug Conjugates ]]>After a brief slump, interest in ADCs is at an all-time high, highlighted by a handful of recent multi-million- and billion-dollar acquisitions. https://www.biospace.com/article/biopharma-bets-big-on-antibody-drug-conjugates/ Mon, 08 May 2023 00:00:00 -0500 https://www.biospace.com/article/biopharma-bets-big-on-antibody-drug-conjugates/ Opinion: Hope on the Horizon for Sjogren’s Syndrome ]]>Despite multiple therapeutics approved to treat localized symptoms, there are currently no systemic therapies on the market for Sjogren’s syndrome. https://www.biospace.com/article/opinion-hope-on-the-horizon-for-sjogren-s-syndrome/ Mon, 08 May 2023 00:00:00 -0500 https://www.biospace.com/article/opinion-hope-on-the-horizon-for-sjogren-s-syndrome/ FDA Action Alert: Sarepta, Protalix, Otsuka/Lundbeck and More ]]>The FDA's agenda includes an advisory committee meeting for Sarepta's delandistrogene moxeparvovec, which, if approved, would become the first gene therapy for Duchenne muscular dystrophy. https://www.biospace.com/article/fda-action-alert-sarepta-protalix-otsuka-lundbeck-and-more/ Mon, 08 May 2023 00:00:00 -0500 https://www.biospace.com/article/fda-action-alert-sarepta-protalix-otsuka-lundbeck-and-more/ FDA Guidance May Bolster Confidence in Decentralized Clinical Trials ]]>The FDA’s new guidance on decentralized clinical trials clarifies how investigators and trial sponsors can use digital health technologies and involve primary healthcare practitioners. https://www.biospace.com/article/fda-guidance-may-bolster-confidence-in-decentralized-clinical-trials/ Mon, 08 May 2023 00:00:00 -0500 https://www.biospace.com/article/fda-guidance-may-bolster-confidence-in-decentralized-clinical-trials/ Legend Biotech Corporation Announces Pricing of Registered Direct Offering of $350 Million of American Depositary Shares Legend Biotech Corporation today announced that it has agreed to sell 5,468,750 American Depositary Shares (“ADSs”), each representing two ordinary shares of the Company, at a price of $64.00 per ADS, in a registered direct offering. https://www.biospace.com/article/releases/legend-biotech-corporation-announces-pricing-of-registered-direct-offering-of-350-million-of-american-depositary-shares/ Mon, 08 May 2023 00:36:00 -0500 https://www.biospace.com/article/releases/legend-biotech-corporation-announces-pricing-of-registered-direct-offering-of-350-million-of-american-depositary-shares/ Incyte Strengthens Research & Development Efforts Appointing Pablo J. Cagnoni, M.D. to New Leadership Role Dr. Cagnoni joins Incyte’s Executive Team as President and Head of Research & Development. https://www.biospace.com/article/releases/incyte-strengthens-research-and-amp-development-efforts-appointing-pablo-j-cagnoni-m-d-to-new-leadership-role/ Mon, 08 May 2023 00:36:00 -0500 https://www.biospace.com/article/releases/incyte-strengthens-research-and-amp-development-efforts-appointing-pablo-j-cagnoni-m-d-to-new-leadership-role/ NLS Pharmaceutics Appoints Keith Harrison Dewedoff as Interim Chief Financial Officer NLS Pharmaceutics Ltd. today announced that Keith Harrison Dewedoff has been appointed to the position of Interim Chief Financial Officer. https://www.biospace.com/article/releases/nls-pharmaceutics-appoints-keith-harrison-dewedoff-as-interim-chief-financial-officer/ Mon, 08 May 2023 00:30:00 -0500 https://www.biospace.com/article/releases/nls-pharmaceutics-appoints-keith-harrison-dewedoff-as-interim-chief-financial-officer/ Virogentics Inc. Announces Pilot Clinical Trial of ITV-1 at National Center for Endocrinology in Bulgaria and Expansion of Nutraceutical Line Enzolytics, Inc. announced that the Company's wholly owned subsidiary, Virogenetics (VIRO), will be conducting a pilot clinical trial test for the state owned Bulgarian National Center for Endocrinology to gauge the effectiveness of the ITV-1 immunotherapy on Diabetes. https://www.biospace.com/article/releases/virogentics-inc-announces-pilot-clinical-trial-of-itv-1-at-national-center-for-endocrinology-in-bulgaria-and-expansion-of-nutraceutical-line/ Mon, 08 May 2023 00:30:00 -0500 https://www.biospace.com/article/releases/virogentics-inc-announces-pilot-clinical-trial-of-itv-1-at-national-center-for-endocrinology-in-bulgaria-and-expansion-of-nutraceutical-line/ Solarea Bio Announces First Close of Series B Financing Round Solarea Bio announced today a first closing of $15m in a Series B financing led by S2G Ventures with continued participation of Bold Capital Partners, Viking Global Investors, and GG 1978 SICAF SIF. https://www.biospace.com/article/releases/solarea-bio-announces-first-close-of-series-b-financing-round/ Mon, 08 May 2023 00:06:00 -0500 https://www.biospace.com/article/releases/solarea-bio-announces-first-close-of-series-b-financing-round/ New Data from Phase 1/2 Trial of INO-3107 for the Treatment of Recurrent Respiratory Papillomatosis Presented at ABEA during COSM 2023 INOVIO presented new data from a Phase 1/2 trial of INO-3107 (NCT:04398433) for the treatment of HPV 6 and HPV 11-associated Recurrent Respiratory Papillomatosis (RRP) on May 5th as part of the scientific program of the American Broncho-Esophagological Association (ABEA) at the Combined Otolaryngology Spring Meetings (COSM) in Boston, Massachusetts. https://www.biospace.com/article/releases/new-data-from-phase-1-2-trial-of-ino-3107-for-the-treatment-of-recurrent-respiratory-papillomatosis-presented-at-abea-during-cosm-2023/ Mon, 08 May 2023 00:06:00 -0500 https://www.biospace.com/article/releases/new-data-from-phase-1-2-trial-of-ino-3107-for-the-treatment-of-recurrent-respiratory-papillomatosis-presented-at-abea-during-cosm-2023/ Recursion Provides Business Updates and Reports First Quarter 2023 Financial Results Recursion (Nasdaq: RXRX), a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery, today reported business updates and financial results for its first quarter ending March 31, 2023. https://www.biospace.com/article/releases/recursion-provides-business-updates-and-reports-first-quarter-2023-financial-results/ Mon, 08 May 2023 00:00:00 -0500 https://www.biospace.com/article/releases/recursion-provides-business-updates-and-reports-first-quarter-2023-financial-results/ Krystal Biotech Announces First Quarter 2023 Financial Results and Operational Highlights Krystal Biotech, Inc. today reported financial results and key operational progress updates for the first quarter ended March 31, 2023. https://www.biospace.com/article/releases/krystal-biotech-announces-first-quarter-2023-financial-results-and-operational-highlights/ Mon, 08 May 2023 00:00:00 -0500 https://www.biospace.com/article/releases/krystal-biotech-announces-first-quarter-2023-financial-results-and-operational-highlights/ Temple Therapeutics Reveals Breakthrough Findings on Ovarian Cancer at AACR 2023 Temple Therapeutics presented new in vitro and in vivo data on TTX335o, the first drug candidate from the company’s platform that won the Eurostar Eureka peer-reviewed grant process in 2019 for ovarian cancer. https://www.biospace.com/article/releases/temple-therapeutics-reveals-breakthrough-findings-on-ovarian-cancer-at-aacr-2023/ Mon, 08 May 2023 00:16:00 -0500 https://www.biospace.com/article/releases/temple-therapeutics-reveals-breakthrough-findings-on-ovarian-cancer-at-aacr-2023/ Life Biosciences and Forge Biologics Announce cGMP Manufacturing Partnership to Advance Development of Novel Gene Therapies for Aging-Related Diseases Life Biosciences and Forge Biologics today announced a manufacturing partnership to help advance Life Bio’s partial epigenetic reprogramming platform to address aging-related diseases, including its lead program targeting ophthalmic indications. https://www.biospace.com/article/releases/life-biosciences-and-forge-biologics-announce-cgmp-manufacturing-partnership-to-advance-development-of-novel-gene-therapies-for-aging-related-diseases/ Mon, 08 May 2023 00:16:00 -0500 https://www.biospace.com/article/releases/life-biosciences-and-forge-biologics-announce-cgmp-manufacturing-partnership-to-advance-development-of-novel-gene-therapies-for-aging-related-diseases/ Natera Announces New Publication from I-SPY2 Trial Reinforcing Clinical Utility of Signatera™ for Breast Cancer Patients in the Neoadjuvant Setting Natera, Inc. today announced the publication of a new paper 1 in Cancer Cell from the I-SPY2 trial, highlighting the prognostic and predictive utility of Natera’s personalized and tumor-informed, molecular residual disease (MRD) test, Signatera, in locally advanced breast cancer patients receiving neoadjuvant chemotherapy (NAC, treatment before surgery). https://www.biospace.com/article/releases/natera-announces-new-publication-from-i-spy2-trial-reinforcing-clinical-utility-of-signatera-for-breast-cancer-patients-in-the-neoadjuvant-setting/ Mon, 08 May 2023 00:16:00 -0500 https://www.biospace.com/article/releases/natera-announces-new-publication-from-i-spy2-trial-reinforcing-clinical-utility-of-signatera-for-breast-cancer-patients-in-the-neoadjuvant-setting/ AceLink Therapeutics Appoints Pedro Huertas, M.D., Ph.D., as Chief Medical Officer AceLink Therapeutics, Inc. today announced the appointment of Pedro Huertas, M.D., Ph.D., as Chief Medical Officer (CMO). https://www.biospace.com/article/releases/acelink-therapeutics-appoints-pedro-huertas-m-d-ph-d-as-chief-medical-officer/ Mon, 08 May 2023 00:16:00 -0500 https://www.biospace.com/article/releases/acelink-therapeutics-appoints-pedro-huertas-m-d-ph-d-as-chief-medical-officer/